Rizzo, Federica http://orcid.org/0000-0002-5945-8222
Romoli, Michele http://orcid.org/0000-0001-8009-8543
Simonetti, Luigi http://orcid.org/0000-0002-5238-4865
Gentile, Mauro http://orcid.org/0000-0002-6912-8868
Forlivesi, Stefano http://orcid.org/0000-0003-0609-3044
Piccolo, Laura http://orcid.org/0000-0002-4641-8352
Naldi, Federica http://orcid.org/0000-0002-7586-3068
Paolucci, Matteo http://orcid.org/0000-0002-5347-378X
Galluzzo, Simone
Taglialatela, Francesco
Princiotta, Ciro
Migliaccio, Ludovica http://orcid.org/0000-0001-7110-4892
Petruzzellis, Marco
Logroscino, Giancarlo http://orcid.org/0000-0003-0423-3242
Zini, Andrea http://orcid.org/0000-0003-1486-4507
Article History
Received: 8 May 2023
Accepted: 24 September 2023
First Online: 6 October 2023
Declarations
:
: Ethical approval was not sought for the present study because the study was nested within the local stroke registry.
: The authors declare no competing interests. Relevant disclosures outside the submitted work: AZ declares consulting fees from Boehringer-Ingelheim, Alexion, and CLS Behring and declares grant from the Italian Ministry of Health as principal investigator for clinical trial (RF-2019–12370834). DT reports fees for advisory board and speaker honoraria from Abbott, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, and Pfizer.